Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Cannot have received: anti-PD-1 therapy

Exception: allowed if used for another malignancy and completed >2 years ago

Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent as monotherapy or as combination therapy for uveal melanoma. Note: these agents may have been used for the treatment of another malignancy as long as the therapy was completed more than 2 years ago

Cannot have received: PARP inhibitor

Has received prior PARP inhibitor therapy

Cannot have received: systemic anti-cancer therapy

Exception: allowed if >4 weeks (or 5 half-lives) prior to study therapy

Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks [or 5 half-lives of the agent, whichever is shorter] prior to planned start of study therapy

Cannot have received: radiotherapy

Exception: allowed if >2 weeks prior to study intervention; 1-week washout permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease

Has received prior radiotherapy within 2 weeks of start of study intervention. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease